Vericel (NASDAQ:VCEL) Stock: Insider Jonathan Siegal Sells 1,500 Shares

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Siegal sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $52.90, for a total value of $79,350.00. Following the completion of the transaction, the insider owned 1,259 shares of the company’s stock, valued at approximately $66,601.10. This represents a 54.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vericel Trading Up 5.5%

Shares of NASDAQ:VCEL traded up $2.84 during trading on Friday, hitting $54.62. 1,612,332 shares of the company were exchanged, compared to its average volume of 598,922. Vericel Corporation has a fifty-two week low of $28.95 and a fifty-two week high of $55.60. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 116.22 and a beta of 1.08. The firm has a fifty day moving average price of $40.74 and a two-hundred day moving average price of $38.80.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.06 by $0.21. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The company had revenue of $85.37 million during the quarter, compared to the consensus estimate of $77.95 million. During the same quarter in the prior year, the firm posted $0.10 EPS. The firm’s revenue for the quarter was up 26.5% compared to the same quarter last year. As a group, research analysts predict that Vericel Corporation will post 0.54 EPS for the current year.

Institutional Trading of Vericel

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Allworth Financial LP grew its position in shares of Vericel by 53.0% in the third quarter. Allworth Financial LP now owns 2,052 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 711 shares during the last quarter. Gagnon Securities LLC raised its stake in Vericel by 7.3% in the 3rd quarter. Gagnon Securities LLC now owns 7,839 shares of the biotechnology company’s stock worth $315,000 after purchasing an additional 536 shares in the last quarter. Maryland State Retirement & Pension System raised its stake in Vericel by 53.3% in the 3rd quarter. Maryland State Retirement & Pension System now owns 11,395 shares of the biotechnology company’s stock worth $457,000 after purchasing an additional 3,963 shares in the last quarter. Illinois Municipal Retirement Fund bought a new stake in Vericel in the 3rd quarter valued at about $1,071,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Vericel by 0.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 157,081 shares of the biotechnology company’s stock valued at $6,195,000 after purchasing an additional 435 shares during the period.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on VCEL shares. HC Wainwright raised their target price on shares of Vericel from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Friday. Truist Financial set a $65.00 price target on Vericel in a research report on Friday. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. TD Cowen raised their price objective on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Canaccord Genuity Group set a $60.00 target price on Vericel in a research note on Thursday, July 30th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Vericel presently has an average rating of “Moderate Buy” and a consensus price target of $60.80.

Trending Headlines about Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, while earnings were $0.27 per share—well above analyst estimates. Net income increased 179% to $14.2 million; the company also cited record MACI sales. Vericel Q3 2026 results and guidance
• Positive Sentiment: Vericel raised its 2026 revenue guidance to $344–$346 million, above the approximately $336 million consensus, and increased its adjusted EBITDA margin guidance to 28%. Vericel Q3 2026 results and guidance
• Positive Sentiment: HC Wainwright raised its price target from $72 to $75 and reaffirmed a Buy rating, signaling continued analyst confidence after the results. HC Wainwright raises Vericel price target
• Negative Sentiment: A separate analysis described VCEL as potentially overvalued relative to its earnings support, a risk if future growth does not justify investor expectations. Analysis of Vericel’s valuation

About Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.